Risk factors for potential drug–drug interactions in patients with myasthenia gravis

Aleksić, D; Milosavljević, Mirjana; Stefanović, Sofija; Bukonjić, Andriana M.; Milosavljevic, Jovana; Janković, Slobodan M.; Božović, Ivo; Perić, Stojan; Lavrnić, Dragana

doi:10.1080/01616412.2021.1948767

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To prevent atherothrombotic events, they receive antiplatelet agents, usually acetylsalicylic acid, for primary and secondary prevention ( 33 ). Considering that antiplatelet drugs tend to interact with other drugs due to their pharmacokinetic and pharmacodynamic properties ( 34 ), the results obtained are not surprising. Antithrombotics are the most common group of drugs with which major DDIs occur ( 25 , 26 , 35 , 36 ).…”

Section: Discussionmentioning

confidence: 88%

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Lalatovic

Pantović

Nedović-Vuković³

et al. 2023

ijph

View full text Add to dashboard Cite

Background: Patients with dyslipidemia are usually multimorbid and require polypharmacy. Therefore, it is important to identify potential drug-drug interactions (pDDIs) in time to prevent their consequences. We aimed to identify and analyze risk factors contributing to their occurrence to guide health professionals. Methods: A prospective cross-sectional study of 216 outpatients with dyslipidemia was conducted from May 2021 to April 2022 in Podgorica, the capital of Montenegro. pDDIs were identified using Medscape, Epocra- tes, and Drugs online interaction checkers. Multivariate regression analysis was performed to evaluate the po- tential predictors of interactions. Results: pDDIs were detected in 212 (98.1%) participants, whereas pDDIs with high clinical significance were detected in 25.46%, 40.74%, and 58.8% of subjects by Drugs, Epocrates, and Medscape, respectively. Polypharmacy emerged as a risk factor for the occurrence of pDDIs in all three checkers in each category of clinical significance. The use of non-steroidal anti-inflammatory drugs and antiplatelet drugs contributes to the incidence of severe pDDIs B=1.014, 95%CI 0.681-1.346, P=0.000 and B=0.492, 95%CI 0.286-0.698, P=0.000, by Epocrates and Medscape respectively. The number of prescribers per patient was a protective factor against moderate pDDI B= -0.858, 95%CI -1.572-(-0.144), P=0.019 and B= -0.956, 95%CI -1.671-(- 0.241), P=0.009, by Medscape and Epocrates, respectively, but a risk factor for the occurrence of minor pDDIs B=0.373, 95%CI 0.033-0.712 P=0.032 and B=0.143, 95%CI 0.042-0.244, P=0.006, by the same checkers. Conclusion: Knowledge of the risk factors contributing to the occurrence of pDDIs is important for the development and implementation of strategies for their prevention, and given the high prevalence of dyslipidemia, understanding these factors seems crucial nowadays.

show abstract